In vivo efficacy of rutin-loaded nanolipid carrier for the healing and management of diabetic wound

Chronic diabetic wounds, particularly diabetic foot ulcers (DFUs), present significant challenges in clinical management due to impaired healing processes and limitations of conventional treatments. This study explores an innovative approach to diabetic wound care through the development and evaluation of Rutin-loaded Solid Lipid Nanoparticles (RN-SLNs). Rutin, a bioflavonoid with potent anti-inflammatory, antioxidant, and pro-angiogenic properties, was encapsulated within biocompatible lipid nanocarriers to enhance its therapeutic efficacy in wound healing. The RN-SLNs were synthesized using an optimized hot homogenization technique followed by ultrasonication, resulting in a stable nanoformulation. The study aimed to assess the in vivo efficacy of RN-SLNs in managing diabetic wounds, focusing on key healing parameters. This novel drug delivery system addresses the challenges of topical drug administration in chronic wounds, including drug degradation and uncontrolled release. Results demonstrate the potential of RN-SLNs to modulate the wound healing environment, promoting tissue regeneration and mitigating the chronic inflammation characteristic of diabetic wounds. The successful development and evaluation of RN-SLNs represent a significant step towards translating nanotechnology-based approaches into clinical wound care. This research opens avenues for personalized nanomedicine strategies in diabetic wound management, potentially improving patient outcomes and quality of life.